Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders.
In conclusion, the spectrum of molecules interacting at the different levels of HPA axis is exponentially increasing, ranging from supra-hypothalamic targets to post-receptor mechanisms and it includes agents acting on SCN, CRH-R1 receptor, adrenal steroidogenesis, GR and peripheral/central 11β-HSD1 enzyme. This area of research is rapidly advancing in order to develop therapeutic strategies to counteract HPA axis hyperactivity and to reduce the burden of stress-related disorders. The article presented some promising patents on the strategies against glucocorticoid-mediated brain damage.
PMID: 21834781 [PubMed - indexed for MEDLINE]
Source: Recent Patents on CNS Drug Discovery - Category: Drugs & Pharmacology Tags: Recent Pat CNS Drug Discov Source Type: research
More News: Brain | Cardiology | Cardiovascular | Dementia | Depression | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Heart | Hormones | Hyperactivity | Hypertension | Neurology | Obesity